Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Feb 1;101(3):667–676. doi: 10.1172/JCI575

Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.

P Gresele 1, S Momi 1, M Berrettini 1, G G Nenci 1, H P Schwarz 1, N Semeraro 1, M Colucci 1
PMCID: PMC508611  PMID: 9449701

Abstract

Activated protein C (APC) is a potent physiologic anticoagulant with profibrinolytic properties, and has been shown to prevent thrombosis in different experimental models. We investigated the effect of human APC on thrombin-induced thromboembolism in mice, a model of acute intravascular fibrin deposition leading to death within minutes. APC given intravenously (i.v.) as a bolus 2 min before thrombin challenge (1,250 U/kg) reduced mortality in a dose-dependent manner despite the lack of thrombin inhibitor activity. Significant inhibition of thrombin-induced death was observed at the dose of 0.05 mg/kg, and maximal protection was obtained with 2 mg/kg (> 85% reduction in mortality rate). Histology of lung tissue revealed that APC treatment (2 mg/kg) reduced significantly vascular occlusion rate (from 89.2 to 46.6%, P < 0.01). The protective effect of APC was due to the inhibition of endogenous thrombin formation as indicated by the fact that (a) the injection of human thrombin caused a marked decrease in the coagulation factors of the intrinsic and common pathways (but not of Factor VII), suggesting the activation of blood clotting via the contact system; (b) APC pretreatment reduced markedly prothrombin consumption; (c) the lethal effect of thrombin was almost abolished when the animals were made deficient in vitamin K-dependent factors by warfarin treatment, and could be restored only by doubling the dose of thrombin, indicating that the generation of endogenous thrombin contributes significantly to death; and (d) APC failed to protect warfarin-treated animals, in which mortality is entirely due to injected thrombin, even after protein S supplementation. Other results suggest that APC protects from thrombin-induced thromboembolism by rendering the formed fibrin more susceptible to plasmin degradation rather than by reducing fibrin formation: in thrombin-treated mice, fibrinogen consumption was not inhibited by APC; and inhibition of endogenous fibrinolysis by epsilon-aminocaproic or tranexamic acid resulted in a significant reduction of the protective effect of APC. Since APC did not enhance plasma fibrinolytic activity, as assessed by the measurement of plasminogen activator (PA) or PA inhibitor (PAI) activities, PAI-1 antigen, or 125I-fibrin degrading activity, we speculate that the inhibition of additional (endogenous) thrombin formation by APC interrupts thrombin-dependent mechanisms that make fibrin clots more resistant to lysis, so that the intravascular deposited fibrin can be removed more rapidly by the endogenous fibrinolytic system.

Full Text

The Full Text of this article is available as a PDF (278.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bajzar L., Morser J., Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 1996 Jul 12;271(28):16603–16608. doi: 10.1074/jbc.271.28.16603. [DOI] [PubMed] [Google Scholar]
  2. Bajzar L., Nesheim M. E., Tracy P. B. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. 1996 Sep 15;88(6):2093–2100. [PubMed] [Google Scholar]
  3. Bajzár L., Fredenburgh J. C., Nesheim M. The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system. J Biol Chem. 1990 Oct 5;265(28):16948–16954. [PubMed] [Google Scholar]
  4. Bertina R. M., Koeleman B. P., Koster T., Rosendaal F. R., Dirven R. J., de Ronde H., van der Velden P. A., Reitsma P. H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994 May 5;369(6475):64–67. doi: 10.1038/369064a0. [DOI] [PubMed] [Google Scholar]
  5. Burdick M. D., Schaub R. G. Human protein C induces anticoagulation and increased fibrinolytic activity in the cat. Thromb Res. 1987 Feb 15;45(4):413–419. doi: 10.1016/0049-3848(87)90230-1. [DOI] [PubMed] [Google Scholar]
  6. Colucci M., Stassen J. M., Collen D. Influence of protein C activation on blood coagulation and fibrinolysis in squirrel monkeys. J Clin Invest. 1984 Jul;74(1):200–204. doi: 10.1172/JCI111402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Colucci M., Triggiani R., Cavallo L. G., Semeraro N. Thrombin infusion in endotoxin-treated rabbits reduces the plasma levels of plasminogen activator inhibitor: evidence for a protein-C-mediated mechanism. Blood. 1989 Nov 1;74(6):1976–1982. [PubMed] [Google Scholar]
  8. Comp P. C., Esmon C. T. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest. 1981 Nov;68(5):1221–1228. doi: 10.1172/JCI110368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dahlbäck B., Carlsson M., Svensson P. J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1004–1008. doi: 10.1073/pnas.90.3.1004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Declerck P. J., Verstreken M., Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost. 1995 Nov;74(5):1305–1309. [PubMed] [Google Scholar]
  11. Dejana E., Villa S., de Gaetano G. Bleeding time in rats: a comparison of different experimental conditions. Thromb Haemost. 1982 Aug 24;48(1):108–111. [PubMed] [Google Scholar]
  12. DiMinno G., Silver M. J. Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther. 1983 Apr;225(1):57–60. [PubMed] [Google Scholar]
  13. Dreyfus M., Masterson M., David M., Rivard G. E., Müller F. M., Kreuz W., Beeg T., Minford A., Allgrove J., Cohen J. D. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost. 1995;21(4):371–381. doi: 10.1055/s-2007-1000658. [DOI] [PubMed] [Google Scholar]
  14. Esmon C. T., Taylor F. B., Jr, Snow T. R. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost. 1991 Jul 12;66(1):160–165. [PubMed] [Google Scholar]
  15. Esmon C. T. The protein C anticoagulant pathway. Arterioscler Thromb. 1992 Feb;12(2):135–145. doi: 10.1161/01.atv.12.2.135. [DOI] [PubMed] [Google Scholar]
  16. Gailani D., Broze G. J., Jr Factor XI activation in a revised model of blood coagulation. Science. 1991 Aug 23;253(5022):909–912. doi: 10.1126/science.1652157. [DOI] [PubMed] [Google Scholar]
  17. Gomi K., Zushi M., Honda G., Kawahara S., Matsuzaki O., Kanabayashi T., Yamamoto S., Maruyama I., Suzuki K. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood. 1990 Apr 1;75(7):1396–1399. [PubMed] [Google Scholar]
  18. Gresele P., Corona C., Alberti P., Nenci G. G. Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. Thromb Haemost. 1990 Aug 13;64(1):80–86. [PubMed] [Google Scholar]
  19. Griendling K. K., Alexander R. W. Endothelial control of the cardiovascular system: recent advances. FASEB J. 1996 Feb;10(2):283–292. doi: 10.1096/fasebj.10.2.8641561. [DOI] [PubMed] [Google Scholar]
  20. Gruber A., Griffin J. H. Direct detection of activated protein C in blood from human subjects. Blood. 1992 May 1;79(9):2340–2348. [PubMed] [Google Scholar]
  21. Gruber A., Griffin J. H., Harker L. A., Hanson S. R. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood. 1989 Feb 15;73(3):639–642. [PubMed] [Google Scholar]
  22. Gruber A., Mori E., del Zoppo G. J., Waxman L., Griffin J. H. Alteration of fibrin network by activated protein C. Blood. 1994 May 1;83(9):2541–2548. [PubMed] [Google Scholar]
  23. Krishnamurti C., Young G. D., Barr C. F., Colleton C. A., Alving B. M. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits. J Lab Clin Med. 1991 Dec;118(6):523–530. [PubMed] [Google Scholar]
  24. Kumada T., Dittman W. A., Majerus P. W. A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice. Blood. 1988 Mar;71(3):728–733. [PubMed] [Google Scholar]
  25. Lane D. A., Mannucci P. M., Bauer K. A., Bertina R. M., Bochkov N. P., Boulyjenkov V., Chandy M., Dahlbäck B., Ginter E. K., Miletich J. P. Inherited thrombophilia: Part 1. Thromb Haemost. 1996 Nov;76(5):651–662. [PubMed] [Google Scholar]
  26. Moroz L. A., Gilmore N. J. A rapid and sensitive 125I-fibrin solid-phase fibrinolytic assay for plasmin. Blood. 1975 Oct;46(4):543–553. [PubMed] [Google Scholar]
  27. Okajima K., Imamura H., Koga S., Inoue M., Takatsuki K., Aoki N. Treatment of patients with disseminated intravascular coagulation by protein C. Am J Hematol. 1990 Apr;33(4):277–278. doi: 10.1002/ajh.2830330413. [DOI] [PubMed] [Google Scholar]
  28. Okajima K., Koga S., Kaji M., Inoue M., Nakagaki T., Funatsu A., Okabe H., Takatsuki K., Aoki N. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost. 1990 Feb 19;63(1):48–53. [PubMed] [Google Scholar]
  29. Rabiet M. J., Plantier J. L., Dejana E. Thrombin-induced endothelial cell dysfunction. Br Med Bull. 1994 Oct;50(4):936–945. doi: 10.1093/oxfordjournals.bmb.a072935. [DOI] [PubMed] [Google Scholar]
  30. Rapaport S. I., Rao L. V. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb. 1992 Oct;12(10):1111–1121. doi: 10.1161/01.atv.12.10.1111. [DOI] [PubMed] [Google Scholar]
  31. Sakata Y., Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest. 1980 Feb;65(2):290–297. doi: 10.1172/JCI109671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sakata Y., Loskutoff D. J., Gladson C. L., Hekman C. M., Griffin J. H. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood. 1986 Dec;68(6):1218–1223. [PubMed] [Google Scholar]
  33. Sakharov D. V., Plow E. F., Rijken D. C. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem. 1997 May 30;272(22):14477–14482. doi: 10.1074/jbc.272.22.14477. [DOI] [PubMed] [Google Scholar]
  34. Taylor F. B., Jr, Chang A., Esmon C. T., D'Angelo A., Vigano-D'Angelo S., Blick K. E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987 Mar;79(3):918–925. doi: 10.1172/JCI112902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Uchiba M., Okajima K., Murakami K., Nawa K., Okabe H., Takatsuki K. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thromb Haemost. 1995 Nov;74(5):1265–1270. [PubMed] [Google Scholar]
  36. Von dem Borne P. A., Bajzar L., Meijers J. C., Nesheim M. E., Bouma B. N. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest. 1997 May 15;99(10):2323–2327. doi: 10.1172/JCI119412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Váradi K., Philapitsch A., Santa T., Schwarz H. P. Activation and inactivation of human protein C by plasmin. Thromb Haemost. 1994 May;71(5):615–621. [PubMed] [Google Scholar]
  38. Warn-Cramer B. J., Rapaport S. I. Evidence suggestive of activation of the intrinsic pathway of blood coagulation after injection of factor Xa/phospholipid into rabbits. Arterioscler Thromb Vasc Biol. 1995 Jan;15(1):133–139. doi: 10.1161/01.atv.15.1.133. [DOI] [PubMed] [Google Scholar]
  39. Yamashita T., Matsuoka A., Funatsu A., Yamamoto J. The antithrombotic effect of human activated protein C on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb Res. 1994 Jul 1;75(1):33–40. doi: 10.1016/0049-3848(94)90137-6. [DOI] [PubMed] [Google Scholar]
  40. de Fouw N. J., Haverkate F., Bertina R. M. Protein C and fibrinolysis: a link between coagulation and fibrinolysis. Adv Exp Med Biol. 1990;281:235–243. doi: 10.1007/978-1-4615-3806-6_23. [DOI] [PubMed] [Google Scholar]
  41. van Giezen J. J., Chung-A-Hing J. E., Vegter C. B., Bouma B. N., Jansen J. W. Fibrinolytic activity in blood is distributed over a cellular and the plasma fraction which can be modulated separately. Thromb Haemost. 1994 Dec;72(6):887–892. [PubMed] [Google Scholar]
  42. von dem Borne P. A., Meijers J. C., Bouma B. N. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood. 1995 Oct 15;86(8):3035–3042. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES